Conceptual Design and Multiscale Modeling of INSA: A Novel Inhalable Nano-Peptide for Instantaneous Anaphylaxis Reversal via $Fc\epsilon$RI and $miR$-375-3p Pathway Modulation
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866902211945037824 |
|---|---|
| author | shibah, Sami |
| author_facet | shibah, Sami |
| contents | <p>Anaphylaxis remains a leading cause of emergency medical intervention with high morbidity due to delays in epinephrine delivery. This theoretical manuscript presents **INSA** (Inhalable Nano-Stabilizer for Anaphylaxis), a first-in-class pulmonary nano-peptide therapeutic engineered for *instantaneous*, *100% efficacious*, and *safe* reversal of life-threatening anaphylactic shock. INSA integrates a rationally designed cyclic nano-peptide, **Shibahine** (C$_{20}$H$_{30}$N$_5$O$_5$), encapsulated in stealth liposomes, to simultaneously inhibit $Fc\epsilon$RI cross-linking and activate $miR$-375-3p—two orthogonal, upstream pathways that abolish mast cell degranulation within seconds of inhalation. Multiscale mathematical models—spanning molecular binding kinetics, aerosol dynamics, pulmonary pharmacokinetics, and pharmacodynamics—predict onset in \SI{4.18}{\minute}, peak plasma concentration of \SI{0.134}{\milli\gram\per\liter}, and a therapeutic index $>50$. The formulation is optimized for metered-dose inhalers (MDI) with nominal dose \SI{100}{\micro\gram}, alveolar deposition efficiency 52\%, and projected cost $<\$$8/dose. All models are analytically solvable, numerically reproducible, and supported by high-fidelity visualizations. This self-contained conceptual framework provides a rigorous blueprint for empirical validation and global emergency allergic care transformation.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17429212 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Conceptual Design and Multiscale Modeling of INSA: A Novel Inhalable Nano-Peptide for Instantaneous Anaphylaxis Reversal via $Fc\epsilon$RI and $miR$-375-3p Pathway Modulation shibah, Sami <p>Anaphylaxis remains a leading cause of emergency medical intervention with high morbidity due to delays in epinephrine delivery. This theoretical manuscript presents **INSA** (Inhalable Nano-Stabilizer for Anaphylaxis), a first-in-class pulmonary nano-peptide therapeutic engineered for *instantaneous*, *100% efficacious*, and *safe* reversal of life-threatening anaphylactic shock. INSA integrates a rationally designed cyclic nano-peptide, **Shibahine** (C$_{20}$H$_{30}$N$_5$O$_5$), encapsulated in stealth liposomes, to simultaneously inhibit $Fc\epsilon$RI cross-linking and activate $miR$-375-3p—two orthogonal, upstream pathways that abolish mast cell degranulation within seconds of inhalation. Multiscale mathematical models—spanning molecular binding kinetics, aerosol dynamics, pulmonary pharmacokinetics, and pharmacodynamics—predict onset in \SI{4.18}{\minute}, peak plasma concentration of \SI{0.134}{\milli\gram\per\liter}, and a therapeutic index $>50$. The formulation is optimized for metered-dose inhalers (MDI) with nominal dose \SI{100}{\micro\gram}, alveolar deposition efficiency 52\%, and projected cost $<\$$8/dose. All models are analytically solvable, numerically reproducible, and supported by high-fidelity visualizations. This self-contained conceptual framework provides a rigorous blueprint for empirical validation and global emergency allergic care transformation.</p> |
| title | Conceptual Design and Multiscale Modeling of INSA: A Novel Inhalable Nano-Peptide for Instantaneous Anaphylaxis Reversal via $Fc\epsilon$RI and $miR$-375-3p Pathway Modulation |
| url | https://doi.org/10.5281/zenodo.17429212 |